Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma.
Saved in:
| Title: | Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma. |
|---|---|
| Authors: | Powles T; Barts Cancer Institute, Queen Mary University of London, London, UK. thomas.powles1@nhs.net., Choueiri TK; Dana-Farber Cancer Center, Boston, MA, USA., Motzer RJ; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Jonasch E; University of Texas MD Anderson Cancer Center, Houston, TX, USA., Pal S; City of Hope National Medical Center, Duarte, CA, USA., Tannir NM; University of Texas MD Anderson Cancer Center, Houston, TX, USA., Signoretti S; Brigham and Women's Hospital, Boston, MA, USA., Kaldate R; Exelixis, Inc, Alameda, CA, USA., Scheffold C; Exelixis, Inc, Alameda, CA, USA., Wang E; Exelixis, Inc, Alameda, CA, USA., Aftab DT; Exelixis, Inc, Alameda, CA, USA., Escudier B; Gustave-Roussy, Villejuif, France., George DJ; Duke Cancer Institute, Durham, NC, USA. |
| Source: | BMC cancer [BMC Cancer] 2021 Sep 15; Vol. 21 (1), pp. 1023. Date of Electronic Publication: 2021 Sep 15. |
| Publication Type: | Published Erratum |
| Journal Info: | Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE; PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1471-2407 |
|---|---|
| DOI: | 10.1186/s12885-021-08693-9 |
